These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37366520)

  • 1. Stressed stability and protective efficacy of lead lyophilized formulations of ID93+GLA-SE tuberculosis vaccine.
    Archer MC; McCollum J; Press C; Dutill TS; Liang H; Fedor D; Kapilow-Cohen L; Gerhardt A; Phan T; Trappler EH; Orr MT; Kramer RM; Fox CB
    Heliyon; 2023 Jun; 9(6):e17325. PubMed ID: 37366520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lyophilization Process Engineering and Thermostability of ID93 + GLA-SE, a Single-Vial Adjuvanted Subunit Tuberculosis Vaccine Candidate for Use in Clinical Studies.
    Dutill TS; Archer MC; McCollum J; Press C; McNeill L; Hawkins L; Phan T; Laursen E; Cabullos R; Bouchard L; Castro RJ; Lin MW; Roco J; Blois C; Adeagbo B; Guderian JA; Gerhardt A; Beckmann AM; Trappler EH; Kramer RM; Fox CB
    Front Drug Deliv; 2022; 2():. PubMed ID: 37771324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylactic efficacy against Mycobacterium tuberculosis using ID93 and lipid-based adjuvant formulations in the mouse model.
    Baldwin SL; Reese VA; Larsen SE; Beebe E; Guderian J; Orr MT; Fox CB; Reed SG; Coler RN
    PLoS One; 2021; 16(3):e0247990. PubMed ID: 33705411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K.
    Cha SB; Kim WS; Kim JS; Kim H; Kwon KW; Han SJ; Cho SN; Coler RN; Reed SG; Shin SJ
    Vaccine; 2016 Apr; 34(19):2179-87. PubMed ID: 27005808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant formulation structure and composition are critical for the development of an effective vaccine against tuberculosis.
    Orr MT; Fox CB; Baldwin SL; Sivananthan SJ; Lucas E; Lin S; Phan T; Moon JJ; Vedvick TS; Reed SG; Coler RN
    J Control Release; 2013 Nov; 172(1):190-200. PubMed ID: 23933525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model.
    Kwon KW; Lee A; Larsen SE; Baldwin SL; Coler RN; Reed SG; Cho SN; Ha SJ; Shin SJ
    Sci Rep; 2019 Oct; 9(1):15560. PubMed ID: 31664157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy.
    Orr MT; Beebe EA; Hudson TE; Argilla D; Huang PW; Reese VA; Fox CB; Reed SG; Coler RN
    Vaccine; 2015 Nov; 33(48):6570-8. PubMed ID: 26541135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of a thermostable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults.
    Sagawa ZK; Goman C; Frevol A; Blazevic A; Tennant J; Fisher B; Day T; Jackson S; Lemiale F; Toussaint L; Kalisz I; Jiang J; Ondrejcek L; Mohamath R; Vergara J; Lew A; Beckmann AM; Casper C; Hoft DF; Fox CB
    Nat Commun; 2023 Mar; 14(1):1138. PubMed ID: 36878897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a thermostable nanoemulsion adjuvanted vaccine against tuberculosis using a design-of-experiments approach.
    Kramer RM; Archer MC; Orr MT; Dubois Cauwelaert N; Beebe EA; Huang PD; Dowling QM; Schwartz AM; Fedor DM; Vedvick TS; Fox CB
    Int J Nanomedicine; 2018; 13():3689-3711. PubMed ID: 29983563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Testing of a Spray-Dried Tuberculosis Vaccine Candidate in a Mouse Model.
    Gomez M; Ahmed M; Das S; McCollum J; Mellett L; Swanson R; Gupta A; Carrigy NB; Wang H; Barona D; Bachchhav S; Gerhardt A; Press C; Archer MC; Liang H; Seydoux E; Kramer RM; Kuehl PJ; Vehring R; Khader SA; Fox CB
    Front Pharmacol; 2021; 12():799034. PubMed ID: 35126135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dual TLR agonist adjuvant enhances the immunogenicity and protective efficacy of the tuberculosis vaccine antigen ID93.
    Orr MT; Beebe EA; Hudson TE; Moon JJ; Fox CB; Reed SG; Coler RN
    PLoS One; 2014; 9(1):e83884. PubMed ID: 24404140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lyophilization of an Adjuvanted Mycobacterium tuberculosis Vaccine in a Single-Chamber Pharmaceutical Cartridge.
    Barnes V L; Fedor DM; Williams S; Dowling QM; Archer MC; Cloutier S; Parker S; Vedvick TS; Fox CB; Kramer RM
    AAPS PharmSciTech; 2017 Aug; 18(6):2077-2084. PubMed ID: 28000085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a formulation platform for a spray-dried, inhalable tuberculosis vaccine candidate.
    Gomez M; McCollum J; Wang H; Ordoubadi M; Jar C; Carrigy NB; Barona D; Tetreau I; Archer M; Gerhardt A; Press C; Fox CB; Kramer RM; Vehring R
    Int J Pharm; 2021 Jan; 593():120121. PubMed ID: 33278492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy against
    Baldwin SL; Reese VA; Larsen SE; Pecor T; Brown BP; Granger B; Podell BK; Fox CB; Reed SG; Coler RN
    Front Microbiol; 2022; 13():935444. PubMed ID: 36090093
    [No Abstract]   [Full Text] [Related]  

  • 15. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
    Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
    Coler RN; Day TA; Ellis R; Piazza FM; Beckmann AM; Vergara J; Rolf T; Lu L; Alter G; Hokey D; Jayashankar L; Walker R; Snowden MA; Evans T; Ginsberg A; Reed SG;
    NPJ Vaccines; 2018; 3():34. PubMed ID: 30210819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
    Day TA; Penn-Nicholson A; Luabeya AKK; Fiore-Gartland A; Du Plessis N; Loxton AG; Vergara J; Rolf TA; Reid TD; Toefy A; Shenje J; Geldenhuys H; Tameris M; Mabwe S; Bilek N; Bekker LG; Diacon A; Walzl G; Ashman J; Frevol A; Sagawa ZK; Lindestam Arlehamn C; Sette A; Reed SG; Coler RN; Scriba TJ; Hatherill M;
    Lancet Respir Med; 2021 Apr; 9(4):373-386. PubMed ID: 33306991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermostable Ebola virus vaccine formulations lyophilized in the presence of aluminum hydroxide.
    Chisholm CF; Kang TJ; Dong M; Lewis K; Namekar M; Lehrer AT; Randolph TW
    Eur J Pharm Biopharm; 2019 Mar; 136():213-220. PubMed ID: 30703544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against Mycobacterium leprae infection by the ID83/GLA-SE and ID93/GLA-SE vaccines developed for tuberculosis.
    Duthie MS; Coler RN; Laurance JD; Sampaio LH; Oliveira RM; Sousa AL; Stefani MM; Maeda Y; Matsuoka M; Makino M; Reed SG
    Infect Immun; 2014 Sep; 82(9):3979-85. PubMed ID: 25024362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of multidose thermotolerant formulations of a vector-based Covid-19 vaccine candidate, NDV-HXP-S in different product formats: Stability and preservative efficacy study.
    Bzami A; Zhu C; Estrada M; White JA; Lal M
    Vaccine X; 2024 Oct; 20():100535. PubMed ID: 39189025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.